This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Delayed clinical trial data delivery is a growing problem for pharmaceutical companies and one that can have catastrophic consequences for the development of their promising pipeline candidates. But there are ways to improve this situation, as Remarque Systems’ recent Is a lack of real-time data holding trials back?
Their findings, published in the September 2018 research report Challenges and Opportunities in Clinical Data Management, underscore the severity of the problem. Delayed data delivery. Study data is typically collected by internal and external partners. Potentially catastrophic setbacks. That’s transformative.
Increased study adherence: Patients are most familiar with their own devices, and the ability to download an application and complete entries on a device they understand increases their adherence to the study requirements. Prior to joining IQVIA in 2018, J.C. With more than 20 years of industry experience, J.C.
Based on robust data flows, aspects and required controls can be assessed in detail—for example, manual dataentry, interfaces between systems, media change, data conversion, data migration, and data archiving. Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments.”
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content